Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Crafted for Cannabis Connoisseurs, Planet 13 Launches its New Line of Medizin Solventless Live Rosin Vape Cartridges

Leave a comment


The first premium strains launched are Medizin Silver Reserve and Medizin GMO. They are now available at Planet 13’s Medizin Dispensary at 4850 W. Sunset Road, Las Vegas.

For those who want an invigorating and energizing experience, Medizin Silver Reserve is a highly sought-after sativa-dominant hybrid strain, beloved by cannabis enthusiasts for its exceptional balance between uplifting and relaxing effects.

Medizin GMO also known as “Garlic Cookies,” is a potent indica-dominant hybrid strain created by crossing Girl Scout Cookies with Chemdawg. Known for its unique flavor profile and powerful effects, GMO is a strain that leaves a lasting impression.

“We are constantly innovating and offering our customers the best new products,” said David Farris, Planet 13 VP of Sales & Marketing. “Based on the early feedback we’ve received we know our new Medizin Live Rosin Vape Carts will be very popular and we look forward to rolling out additional premium strains.”

For more information, and to shop online or in store visit: https://www.planet13dispensaries.com/

About Planet 13
Planet 13 (http://www.planet13holdings.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations in Las Vegas and Orange County, California. Planet 13 also holds a medical marijuana treatment center license in Florida and a conditional Social-Equity Justice Involved dispensing license in the Chicago region of Illinois. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and create innovative cannabis products. Licensed cannabis activity is legal in these states but remains illegal under U.S. federal law. Planet 13’s shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and are quoted on the OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information
This news release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are often, but not always, identified by phrases such as “plans”, “expects”, “proposed”, “may”, “could”, “would”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases. In this news release, forward-looking statements relate to the launch of Medizin Solventless Live Rosin Vape Cartridges and subsequent performance. Such forward-looking statements reflect what management of the Company believes, or believed at the time, to be reasonable assumptions and accordingly readers are cautioned not to place undue reliance upon such forward-looking statements and that actual results may vary from such forward-looking statements. These assumptions, risks and uncertainties which may cause actual results to differ include, among others, the potential that regulatory approval of the proposed transaction may not be received or may be delayed or that other conditions to the closing of the proposed transaction may not be satisfied, the potential impact on the Company’s business or stock price due to the announcement of the proposed transaction, the occurrence of any event, change or other circumstances that could give rise to the termination of the Purchase Agreement and those assumptions, risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and any of the Company’s subsequent periodic reports filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and on SEDAR at http://www.sedar.com. Forward-looking statements contained herein are made only as to the date of this press release and we assume no obligation to update or revise any forward-looking statements should they change, except as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further inquiries, please contact:
LodeRock Advisors Inc., Planet 13 Investor Relations
[email protected]

Robert Groesbeck or Larry Scheffler
Co-Chief Executive Officers
[email protected]

Media inquiries:
Colin Trethewey / PRmediaNow Communications
[email protected]

Media Contact

Colin Trethewey, Planet 13, 813.480.1354, [email protected], https://www.planet13dispensaries.com/

SOURCE Planet 13

Lifestyle: Self Help

Filmmakers to champion the FSHD Society’s Los Angeles Walk & Roll to Cure FSH muscular dystrophy

Leave a comment


The Good Bad Things team has direct ties to FSHD. Kurtzman, a 35-year-old from Costa Mesa, California, was diagnosed with facioscapulohumeral muscular dystrophy (FSHD) as a child. He co-wrote the script with childhood friend and filmmaker Shane Stanger. Besides Adler, the film also features Brett Dier (Jane the Virgin, Schooled, About My Father) and Jessica Parker Kennedy (Black Sails, The Flash TV series).

“We all struggle. We all listen to the voices in our heads that tell us we are not enough,” says Kurtzman. “This film is for everyone.”

For Max Adler, FSHD is deeply personal. “I watched my mom and Grandma struggle with this disease, and I don’t want that to happen to anyone, anywhere, ever again,” he said. This is Adler’s sixth year serving as national ambassador for the Walk & Roll to Cure FSHD. The fundraiser has grown to involve thousands of participants at 26 locations this year across the U.S. and Canada.

This year’s Walk & Roll aims to raise $1 million dollars to support research into treatments and a cure, as well as life-changing patient support and education services. Expenses for the event are offset by national sponsors Optum, Fulcrum Therapeutics, and Avidity Biosciences, as well as Los Angeles Walk & Roll sponsor The Baked Bear. In addition, the Lai family has pledged to match all donations up to a total of $250,000.

Supporters can donate and/or join a team by registering online for the Los Angeles FSHD Society’s Walk & Roll. Everyone is also encouraged to tune in to the FSHD Society Walk & Roll Facebook Live Celebration on September 23rd. Event participants from coast to coast will call in and Max Adler will make a special appearance.

About the FSHD Society

The FSHD Society is the world’s largest research-focused patient advocacy organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of MD. Over the past 32 years, the organization has catalyzed major advancements and worked to accelerate the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. The FSHD Society has transformed the landscape for FSHD research and is committed to making sure that no one faces this disease alone.

The Society offers a community of support, news, and information through its website.

Media Contact

June Kinoshita, FSHD Society, 781-301-6060, [email protected], https://www.fshdsociety.org/connect/local-chapters/los-angeles-chapter/

Twitter Facebook

SOURCE FSHD Society



health and fitness

A Key Catalyst for FemmePharma’s Latest Innovation in Women’s Health

Leave a comment


Recent Studies Highlight Menopause-Induced Microbiota Changes and Their Health Consequences

PHILADELPHIA, Sept. 14, 2023 /PRNewswire-PRWeb/ — FemmePharma, a leading innovator in women’s wellness products, today announced the launch of their latest breakthrough product, Mia Vita® Women’s Probiotic, a vegetarian and gluten-free oral supplement to support a healthy gut and vaginal microbiome.

Recent studies from the National Library of Medicine have shown that during menopause the gut, vaginal, and urinary microbiota are altered due to drastic hormone changes which may cause several physical changes and subsequent health consequences. This can lead to an imbalance called dysbiosis.

This shift in gut microbiota may contribute to symptoms commonly associated with menopause, such as weight gain, mood changes, and metabolic disruptions. Maintaining a balanced gut microbiome through dietary and lifestyle interventions can play a crucial role in supporting women’s overall health and well-being during this transitional phase.

Backed by extensive research and the expertise of leading experts, Mia Vita® Women’s Probiotic® contains a proprietary blend of beneficial bacteria strains that support optimal gut function, hormonal balance, and immune system support. These carefully selected probiotic strains work in harmony to promote a balanced gut microbiome, helping women feel their best from the inside out.

“We are excited to introduce Mia Vita® Women’s Probiotic supplement as the latest addition to our line of women’s wellness products,” said Gerianne DiPiano, CEO and founder, FemmePharma. “At FemmePharma, we understand that women’s health needs are ever-evolving so we’re empowering women to take charge of their health journey, providing them with a powerful tool to navigate the challenges associated with perimenopause and menopause. This supplement embodies our mission to create tailored solutions that resonate with the unique needs of women.”

Mia Vita® Women’s Probiotic is now available for purchase exclusively on the FemmePharma website Customers and healthcare professionals can learn more about the product’s benefits, ingredients, and usage guidelines on the website.

For media inquiries, please contact Meaghan F. Washington at [email protected] or 215-370-5302.

About FemmePharma

FemmePharma is a pioneering brand dedicated to creating science-backed women’s wellness products that empower women to take control of their health. With a focus on addressing the unique needs and challenges faced by women experiencing symptoms of perimenopause, menopause and postmenopause, FemmePharma develops innovative solutions that promote vitality, balance, and well-being.

Media Contact

Meaghan F. Washington, Francis Goodwin PR LLC, 1 2153705302, hello@francisgoodwinpr.com

SOURCE FemmePharma

Health: Mental Health

New ‘Plutus Health Revenue Cycle Management Challenges Index, 2023’ offers insights into healthcare revenue management

Leave a comment


“Our new ‘Plutus Health Revenue Cycle Management Challenges Index, 2023‘ shows how big of a burden insurance denials are for healthcare providers. With 40% of survey respondents reporting that they are losing more than half a million dollars in annual revenue every year simply because of insurance denials, the scale of the problem is immense,” said Thomas John, Founder and CEO of Plutus Health, Inc.

“Despite AI [artificial intelligence] and RPA [robotic process automation] offering proven solutions, providers still seem hesitant to implement these new technologies into their RCM process. We hope this survey shows just how urgent it is for the healthcare industry as a whole to embrace these new technologies, which have the potential to drastically increase revenue for healthcare providers across the country,” he said.

Claim denials stood out as the top challenge for providers — and it’s costing them a lot of money. More than 40% of the healthcare providers we surveyed said they lose more than half a million U.S. dollars in annual revenue each year due to denied insurance claims. And 18% reported losing more than a million U.S. dollars annually.

Nearly 60% of respondents said that dealing with insurance denials was one of their most significant RCM challenges, and 42% said denial management was one of the stages in their RCM process that is regularly due to staff shortages.

So, it’s no surprise that 43% of respondents said denial management was among their greatest priorities in 2023. And 20% of respondents noted that achieving clean claim rates and lower denial rates were also a top key performance indicator (KPI) that the RCM teams focused on in 2023.

Managing staffing needs also causes stress for healthcare providers, with about 40% of respondents reporting it as one of their most significant challenges. Nearly half of the respondents also revealed that they rely on external support for RCM, either using a combination of internal and external teams or outsourcing to one or more vendors.

Healthcare providers who’ve tried new technologies — such as RPA and AI — have seen improvements in their overall RCM process.

Nearly 20% of the respondents who use AI and RPA said the greatest improvement since implementing the technology was improved efficiency in filing claims, and 18% reported reduced data-entry errors.

Nearly 30% of respondents who used AI and RPA said it resulted in faster cash flow and collections, while about 20% said it resulted in more insightful and readily accessible business analytics.

Bridging the gap between healthcare providers and technology-based solutions is our passion at Plutus Health because we know what it means when we get it right: better patient care.

That’s why we offer services like our claim status-check bots, which leverage automation to make the claim status-check process more efficient and error-free. Additionally, our automated eligibility verification process allows providers to assess eligibility before providing services to a patient or submitting a claim to the Payer.

For more insights into the challenges healthcare providers face in their revenue cycle management and the ways they’ve found to solve them, find more insights as well as the full “Plutus Health Revenue Cycle Management Challenges Index, 2023” report on our website.

Media Contact

Thomas John, Plutus Health Inc., 1 1-469-242-6053, [email protected], www.plutushealthinc.com

LinkedIn

SOURCE Plutus Health Inc.

Health: Addiction

U.S. Career Institute and Premier Health Partner to Support Employee Growth and Solve Staffing Challenges through Education.

Leave a comment


This partnership will enable Premier Health to meet its staffing needs by attracting, developing, and retaining high-quality, Medical Assistants at its affiliated urgent care clinics. Medical Assistants that receive training through U.S. Career Institute will also be positioned to earn industry credentials, ensuring a well-trained, tenured, and patient-focused staff.

“I am excited about this partnership with U.S. Career Institute “stated Jared LeDoux, VP of Human Resources at Premier Health. “In addition to helping build clinical capabilities of our workforce, we are also engaging our front-line team members with opportunities to further their careers. We truly believe, here at Premier Health, that our team members can grow with us – no matter what healthcare path they wish to take. The Medical Assistant program through U.S. Career Institute allows team members the opportunity to learn at their own pace, providing them with instructional support and structured opportunities to practice their skills at the clinic-level.”

Janet Perry, VP of Academics and Compliance at U.S. Career Institute stated, “The rising concerns of labor shortages in the healthcare industry are here to stay, the healthcare industry is facing significant employee shortages from the top down, the U.S. faces a projected shortage of more than 3.2 million skilled healthcare workers such as medical assistants, home health aides and nursing assistants. This partnership contains proven strategies that can help fill critical entry level healthcare positions, while creating career ladders and investment back into the healthcare workforce that will result in developing expertise and retention. U.S. Career Institute is delighted to play a role in solving these challenges.”

About U.S. Career Institute

Weston Distance Learning, the parent company of U.S. Career Institute, has been providing distance education since 1981. By offering high-quality, career-focused online education at affordable prices, U.S. Career Institute has helped thousands of students reach their educational and career goals. U.S. Career Institute is accredited by the Distance Education Accrediting Commission (DEAC), which is listed by the U.S. Department of Education as a recognized accrediting agency. USCI’s curricula, administrative procedures, faculty, and policies are frequently reviewed to make sure that USCI continues to meet high standards of quality and service. To learn more about U.S. Career Institute, visit https://www.partners.uscareerinstitute.edu

About Premier Health

Founded in 1999, Premier Health is among the first urgent care operators in the nation to specialize in a health system branded, joint venture model. A recognized leader in the urgent care industry, Premier Health partners with some of the top health systems across the country including Trinity Health’s and its network of hospitals, HCA, Ardent, LCMC Health, UT Health East Texas and the University of Kansas Health System. Premier Health is committed to the delivery of excellent clinical care in a setting that offers each patient a next-level consumer experience. All of Premier’s clinics are nationally accredited by the Urgent Care Association. You can follow Premier Health on LinkedIn or Twitter. To learn more, go to https://premierhealthurgentcare.com

Media Contact

Holly Cook, U.S. Career Institute, 1 9702826357, [email protected], https://www.partners.uscareerinstitute.edu

SOURCE U.S. Career Institute

Health

Final Call for 2023 Biocodex Microbiota Foundation $50,000 U.S. Research Grant Applications

Leave a comment


Key US-Based Grant Entry Information:

  • Grant Amount: $50,000
  • Eligibility: Applicants must be an advanced degree holder. Grant must be applied to research in a USA institution. Applicant may have no more than 10 years of research experience post-terminal degree (time spent in clinical training is excluded). The grant is intended as a seeding or bridging grant to help investigators initiate or continue a project to become independent.
  • Research Topic: Gut microbiota in human health and disease focusing on groundbreaking areas of research, including, but not limited to, its impact on neurological disorders, oncology, impact on circadian rhythms or other areas of interest.
  • Application Deadline: October 1, 2023
  • Application Entry Email: All completed applications must be sent to [email protected]
  • Winner Announcement/Prizing: December 2023

In 2022, Dr. Harikesh Dubey, who is currently a Postdoctoral Research Associate at the Institute for Quantitative Health Science & Engineering, Michigan State University, received the grant to help further his research on the effect of gut microbiome of humans on brain structure and functions in various mouse models of Autism Spectrum Disorder (ASD).

“The Biocodex Microbiota Foundation grant has given me the opportunity to further my research to better understand the connection between how gut microbiome contribute to co-occurring strengths and challenges in Autism Spectrum Disorder,” says Dr. Dubey. “The findings from this research will help develop a novel microbiome-based intervention to treat Autism Spectrum Disorder and related complications.”

Other previous Biocodex Microbiota Foundation $50,000 grant recipients include:

  • 2021 – Dr. Julia Brown, PhD, for research on the role of the neonatal gut microbiome in lung immune development and antiviral immunity
  • 2020 – Dr. Jessica Queen, MD, PhD, for her work on Fusobacterium strains from colon cancer biopsies
  • 2019 — Dr. Arpana Gupta, PhD., for her research on the prevalence of Metabolic Syndrome (MetS)
  • 2018 — Dr. Tao Yang, PhD., for his investigation into how intestinal microbes may cause dysfunctional gut-brain connections
  • 2017 – Dr. Rashim Singh, PhD, for her research on flavonoids and microbiome interactions via triple recycling and their roles in food-borne carcinogen-induced colorectal cancer

The Biocodex Microbiota Foundation’s annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies. All completed applications that meet entry criteria will be reviewed and one recipient selected. All completed applications should be sent to [email protected] by the October 1, 2023 deadline. Late or incomplete applications, or those that don’t meet the criteria of the grant program or research topic, will not be considered.

To learn more information about Biocodex Microbiota Foundation and the 2023 US grant program, visit here.

About the Biocodex Microbiota Foundation
The Biocodex Microbiota Foundation’s mission is to support research into microbiota and its interaction with various pathologies. Research is supported through grants given to projects that investigate the implication of microbiota in human health. The Biocodex Microbiota Foundation supports both foundational and applied research, and projects are selected annually by a committee of independent scientists.

The foundation’s primary activity remains the awarding of annual grants to innovative scientific research projects that explore the structure and impact of microbiota. In addition, the foundation also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible, including scientific communities and via public projects aimed to help improve human health.

The Biocodex Microbiota Foundation is a non-profit, general interest organization. For more information about the foundation’s international research grants, visit here.

Media Contact

Jessica Russo, RLA Collective, A Ruder Finn Company, 9144242498, [email protected]

SOURCE Biocodex Microbiota Foundation

Health: Mental Health

My Care Labs Earns Union City Award for Outstanding Pandemic Support and Expands Services Globally

Leave a comment


As part of our commitment to comprehensive health solutions, My Care Labs is expanding its horizons with new testing services. Upcoming offerings include Wellness Panels for an in-depth health overview, Drug Testing for both personal and corporate needs, and HR Toxicology Testing prioritizing health in the workplace. Exciting developments also include the establishment of a new Medical Center and plans for a Free Medical Testing Day for the Tri-City community.

Furthermore, our anticipated service additions comprise Cancer Screening for early detection, DOT Physicals for official Department of Transportation evaluations, and Specialty Testing to address complex conditions such as TB, Lyme disease, and mold-related issues.

We are thrilled to announce the launch of My Care International in India, commenced on July 22nd, 2023. This global extension will provide 24/7 Call Center support, exceptional customer assistance, efficient Data Entry Services and much more, all of which underscore our unwavering commitment to healthcare excellence.

To stay connected with My Care Labs, you can easily book appointments online, call us at 1-800-790-4550, or visit our physical location at 5500 Stewart Avenue, Suite 108, Fremont, CA 94538.

For the latest updates and news, be sure to visit our website at www.mycarelabs.com and follow us on our social media platforms:

Facebook

Instagram

Twitter

LinkedIn

We look forward to serving your healthcare needs with dedication and excellence.

Media Contact

Harvey Singh, My Care Labs, 1 8007904550, [email protected], www.mycarelabs.com

Aman Singh, My Care Labs, 1 7607348167, [email protected], www.mycarelabs.com

Twitter

SOURCE My Care Labs



Health

AI startup Carenostics raises $5 million in Seed funding led by M13 to transform healthcare through earlier diagnosis and treatment of chronic disease patients

Leave a comment


A contributing factor to late diagnosis and treatment is overburdened physicians; a recent study from the Journal of General Internal Medicine showed that it would take 27 hours each day for a doctor to follow all acute, chronic and preventive guidelines.

These gaps in healthcare became deeply personal for Kanishka Rao, Carenostics’ Co-founder and COO, when his grandfather succumbed to previously undiagnosed CKD. Carenostics was founded in response to this tragedy.

Carenostics has developed a revolutionary AI platform that identifies undiagnosed and undertreated chronic disease patients and prompts clinicians within their current workflows to intervene earlier. The platform uniquely tailors AI models to each health system using existing, local electronic health record (EHR) data, and supports physicians across multiple diseases. The platform prioritizes patient data privacy, ensuring no information ever leaves the hospital system.

Carenostics has been deployed at leading health systems including Hackensack Meridian Health, the largest hospital system in the state of New Jersey with 17 hospitals and 6 million patient records, to support physicians across an array of chronic conditions.

At Hackensack, Carenostics’ platform has identified up to 3x more chronic kidney disease (CKD) patients and up to 20x more severe and uncontrolled asthma (SUA) patients, while maintaining a 5x lower false positive rate than current care practices. Carenostics has integrated AI insights into existing clinical workflows, demonstrating clinician activation rates up to 5x higher than industry benchmarks.

In addition to Hackensack, Carenostics’ partnerships include AstraZeneca, the VA, and a partnership and investment from Bayer G4A (Bayer’s only early-stage investment of 2022).

Kanishka and his father Dr. Bharat Rao, Co-Founder and CEO of Carenostics, form the core of Carenostics’ veteran leadership team. The team includes more than five AI PhDs; leaders from Siemens, McKinsey, ConcertAI, Cerner, and Amazon; and the team that previously developed the world’s first AI and natural language processing (NLP) solution deployed within EHRs at 300+ health systems.

“Bharat and Kanishka have assembled a world-class leadership team of AI pioneers that were the first to deploy AI at scale on EHR data,” stated Latif Peracha, General Partner at M13. “The future of healthcare is proactive, not reactive, and Carenostics’s use of clinical AI holds the transformative power to overhaul our industry by tackling the costly and life-threatening delays in diagnosis and treatment.”

Dr. Rao said, “We are setting the stage for a data-driven healthcare revolution, where every diagnostic and treatment decision is personalized using patient data and AI.” He holds a PhD in AI, and previously led Healthcare AI for Siemens and KPMG’s US Healthcare & Life Sciences AI & Analytics practice. Notable achievements include the deployment of 20+ FDA- and EU-approved healthcare AI products in 1,000+ global health systems, 150+ peer-reviewed publications, and 60+ AI patents.

Carenostics is also announcing the formation of its advisory board of industry leaders including Kurt Hilzinger, the Chairman of Humana; Dr. John Glaser, former CEO of Siemens Health Services & CIO of Partners Healthcare; Aneesh Chopra, the former Chief Technology Officer of the United States; and Professor Srini Devadas, former associate department chair of Computer Science at MIT.

Carenostics will use its funding to accelerate expansion to many more health systems and chronic conditions.

“Our goal is to stop the story of my grandfather from repeating itself, ultimately improving healthcare outcomes and reducing costs,” said Kanishka Rao. Prior to Carenostics, Rao was a healthtech strategist and led McKinsey’s US Healthcare Startups practice.

For more information, visit https://www.carenostics.com/.

About Carenostics

Carenostics revolutionizes patient care through the application of clinically-oriented artificial intelligence which identifies patients at risk for chronic diseases. The company’s cutting-edge platform seamlessly integrates into clinicians’ workflow leading to faster, earlier diagnosis and treatment for a much greater number of patients.The result is improved patient outcomes and enhanced healthcare efficiency. Carenostics has received awards from Bio-IT World, the National Science Foundation, and the Digital Health Hub Foundation, and their work has been accepted for publication in NeurIPS and AMGA.

For more information, visit https://www.carenostics.com/.

Media Contact

Kanishka Rao, Carenostics, 1 9175355945, [email protected], carenostics.com

SOURCE Carenostics

Health

Labroots Announces Agenda for its 7th Annual Cell Biology Virtual Event Series on September 20, 2023

Leave a comment


This one-day event unveils featured advances in multiple areas of cell biology by leading experts

YORBA LINDA, Calif., Sept. 14, 2023 /PRNewswire-PRWeb/ — Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual Cell Biology event convening on September 20, 2023. The online event is a unique meeting gathering thousands of cell biologists, scientists, research scholars, and experts from leading academia and industry institutions on a global basis. The impactful agenda will focus on the fundamental basis of cell biology and track sessions on translational and quantitative cell biology, exosomes, spatial omics, and Organ-On-A-Chip Technologies.

The Cell Biology Virtual Event Series, a series of scientific meetings produced by Labroots is free to attend and provides an educational forum for registrants and attendees to learn more about emerging interdisciplinary topics in the field of cell biology, not limited to insightful and though-provoking lectures from well-renowned speakers on tools for accelerating research using next-generation cell models, accelerating cell therapies: translational imaging, extracellular vesicles as communicators between cells – a role in cancer dissemination, microfluidic and spleen-on-a-chip studies of sickle cell disease, and microphysiological systems for biomaterials testing and early cancer research.

Just a few highlights kicking off the day, attendees will hear from Dr. Christian Regenbrecht, Co-founder and CEO, Cellphenomics, a sponsored presentation by LUMINEX, a DiaSorin Company titled, “You Like Puzzles? Try to Put the Pieces in Cancer Together” scheduled at 6:00am PDT.

Next, Dr. Danilo A. Tagle, Director of the Office of Special Initiatives at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health will deliver a keynote presentation scheduled at 7:30am PDT titled, “The NIH Microphysiological Systems Program: Tissue on Chips for Safety, Efficacy, and Precision Medicine Studies,” followed by a live Q&A session. Dr. Danilo A. Tagle said, “Exciting technological advances in recent years have led to new opportunities to improve how we predict the safety and efficacy of new drugs in patients. Animal models increasingly have fallen short as risk assessment tools for human response, and the FDA’s willingness to accept data from non-animal models means the time is ripe for newer, more predictive models to evaluate drugs and conduct clinical trials. At NCATS, we’ve spent more than a decade working with our federal partners to support the development of organ-on-a-chip, or tissue chip, technology, to improve disease modeling and drug testing and help speed drugs into clinical trials. At the Labroot’s hosted conference, I plan to discuss the promise of tissue chips as preclinical disease modeling platforms, their usefulness in precision medicine studies, and their future as drug development tools.”

The second keynote presentation scheduled at 9:00am PDT is presented by Dr. Paolo Neviani, Director and Founder, Extracellular Vesicle Core at the Children’s Hospital, Los Angeles, exploring the extracellular vesicle landscape: from biomarker discovery to therapeutics opportunities. Dr. Paolo Neviani stated, “Extracellular vesicles have a tremendous but still untapped potential for clinical applications, such as liquid biopsy biomarkers and as therapeutics. As the understanding of these tiny packets of information expands so do the challenges related to their isolation and characterization. The Children’s Hospital Los Angeles Extracellular Core was founded to help researchers overcome such challenges and accelerate new discoveries. My lecture about extracellular vesicles on the Labroots’ platform will introduce the audience to this exciting research field.”

Produced on Labroots’ partnering virtual event platform, Chati, attendees can connect seamlessly across all desktops and mobile devices while immersed in a comprehensive educational experience. The online environment consists of a lobby equipped with leaderboard and gamification, an auditorium featuring live-streaming video webcasts offering live attendee chats during scheduled presentations, a poster hall featuring a poster competition, live chat conversations, and a scheduled Poster Networking Hour with live poster authors, an exhibit hall to interact with sponsors and view their latest products and technologies, and a networking lounge to connect and collaborate with colleagues. By participating in this event, you can earn 1 Continuing Education credit per watched presentation for a maximum of 30 credits.

To register for the event, click here.

Join the online conversation and use the hashtag #LRcellbio and connect with other members of the global Cell & Molecular Biology community. Follow @CellBiology_LR on Twitter and @CellandMolecularBiology.LR on Facebook to connect with our specialist Cell & Molecular Biology Writers and stay up to date with the latest Trending News in Cell & Molecular Biology.

About Labroots
Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Labroots is a proud partner of Chati, a virtual event platform that allows for the hosting of engaging and interactive virtual and hybrid events, catering to businesses of any vertical or size.

Media Contact

Lynn Brainard, Labroots, 714-771-4397, [email protected], www.labroots.com

Twitter

SOURCE Labroots